Annie Luetkemeyer

Professor
School of Medicine
+1 415 502-5753
Publications: 

Long-term in vitro exposure of Treponema pallidum to sub-bactericidal doxycycline did not induce resistance: Implications for doxy-PEP and syphilis.

The Journal of infectious diseases

Tantalo LC, Luetkemeyer A, Lieberman NAP, Nunley BE, Avendaño C, Greninger AL, Celum C, Giacani L

Long-term in vitro exposure of Treponema pallidum to sub-bactericidal doxycycline did not induce resistance: Implications for doxy-PEP and syphilis.

bioRxiv : the preprint server for biology

Tantalo LC, Luetkemeyer A, P Lieberman NA, Nunley BE, Avendaño C, Greninger AL, Celum C, Giacani L

Community-Based Point-of-Diagnosis Hepatitis C Treatment for Marginalized Populations: A Nonrandomized Controlled Trial.

JAMA network open

Morris MD, McDonell C, Luetkemeyer AF, Thawley R, McKinney J, Price JC

Postexposure Doxycycline for Sexually Transmitted Infections. Reply.

The New England journal of medicine

Luetkemeyer AF, Cannon C, Celum C

Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case.

Open forum infectious diseases

Ortega-Villa AM, Hynes NA, Levine CB, Yang K, Wiley Z, Jilg N, Wang J, Whitaker JA, Colombo CJ, Nayak SU, Kim HJ, Iovine NM, Ince D, Cohen SH, Langer AJ, Wortham JM, Atmar RL, El Sahly HM, Jain MK, Mehta AK, Wolfe CR, Gomez CA, Beresnev T, Mularski RA, Paules CI, Kalil AC, Branche AR, Luetkemeyer A, Zingman BS, Voell J, Whitaker M, Harkins MS, Davey RT, Grossberg R, George SL, Tapson V, Short WR, Ghazaryan V, Benson CA, Dodd LE, Sweeney DA, Tomashek KM

Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial.

Research square

Branche A, Rouphael N, Diemert D, Falsey A, Losada C, Baden LR, Frey S, Whitaker J, Little S, Anderson E, Walter E, Novak R, Rupp R, Jackson L, Babu T, Kottkamp A, Luetkemeyer A, Immergluck L, Presti R, Backer M, Winokur P, Mahgoub S, Goepfert P, Fusco D, Malkin E, Bethony J, Walsh E, Graciaa D, Samaha H, Sherman A, Walsh S, Abate G, Oikonomopoulou Z, Sahly HE, Martin T, Kamidani S, Smith M, Ladner B, Porterfield L, Dunstan M, Wald A, Davis T, Atmar R, Mulligan M, Lyke K, Posavad C, Meagher M, Stephens D, Neuzil K, Abebe K, Hill H, Albert J, Telu K, Mu J, Lewis T, Giebeig L, Eaton A, Netzl A, Wilks S, Tureli S, Makhene M, Crandon S, Montefiori D, Makowski M, Smith D, Nayak S, Roberts P, Beigel J

Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis.

JAMA network open

Troxel AB, Petkova E, Goldfeld K, Liu M, Tarpey T, Wu Y, Wu D, Agarwal A, Avendaño-Solá C, Bainbridge E, Bar KJ, Devos T, Duarte RF, Gharbharan A, Hsue PY, Kumar G, Luetkemeyer AF, Meyfroidt G, Nicola AM, Mukherjee A, Ortigoza MB, Pirofski LA, Rijnders BJA, Rokx C, Sancho-Lopez A, Shaw P, Tebas P, Yoon HA, Grudzen C, Hochman J, Antman EM

Remdesivir for the Treatment of Covid-19 - Final Report.

The New England journal of medicine

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, ACTT-1 Study Group Members

Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence.

Alimentary pharmacology & therapeutics

Sulkowski M, Luetkemeyer AF, Wyles DL, Martorell C, Muir A, Weisberg I, Gordon SC, McLain R, Huhn G

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT, Acquired Immunodeficiency Syndrome Clinical Trials Group (ACTG) A5327 Study Team

A pilot metabolomics study of tuberculosis immune reconstitution inflammatory syndrome.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Silva CAM, Graham B, Webb K, Ashton LV, Harton M, Luetkemeyer AF, Bokatzian S, Almubarak R, Mahapatra S, Hovind L, Kendall MA, Havlir D, Belisle JT, De Groote MA

Localized US Efforts to Eliminate Hepatitis C.

Infectious disease clinics of North America

Gaudino A, Gay B, Garmon C, Selick M, Vreeland R, Burk K, Huriaux E, Facente SN, Luetkemeyer A, Waters P, Graham CS

Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.

Liver international : official journal of the International Association for the Study of the Liver

Tam E, Luetkemeyer AF, Mantry PS, Satapathy SK, Ghali P, Kang M, Haubrich R, Shen X, Ni L, Camus G, Copans A, Rossaro L, Guyer B, Brown RS, RESCUE and ACTG A5348 study investigators

Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure.

Hepatology (Baltimore, Md.)

Wyles D, Wedemeyer H, Ben-Ari Z, Gane EJ, Hansen JB, Jacobson IM, Laursen AL, Luetkemeyer A, Nahass R, Pianko S, Zeuzem S, Jumes P, Huang HC, Butterton J, Robertson M, Wahl J, Barr E, Joeng HK, Martin E, Serfaty L, C-CREST Part C and C-SURGE Investigators

Impact of Larger Sputum Volume on Xpert® MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis.

Journal of clinical medicine

Badal-Faesen S, Firnhaber C, Kendall MA, Wu X, Grinsztejn B, Escada RODS, Fernandez M, Hogg E, Sanne I, Johnson P, Alland D, Mazurek GH, Benator DA, Luetkemeyer AF, AIDS Clinical Trials Group A5295, Tuberculosis Trials Consortium Study 34 Teams

Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.

Open forum infectious diseases

Rockstroh JK, Orkin C, Viani RM, Wyles D, Luetkemeyer AF, Lazzarin A, Soto-Malave R, Nelson MR, Bhagani SR, Klinker HHF, Rizzardini G, Girard PM, Tural C, Shulman NS, Mobashery N, Hu YB, Fredrick LM, Pilot-Matias T, Trinh R, Gane E

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Wyles D, Bräu N, Kottilil S, Daar ES, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Kim AY, Doehle B, Huang KC, Mogalian E, Osinusi A, McNally J, Brainard DM, McHutchison JG, Naggie S, Sulkowski M, ASTRAL-5 Investigators

CROI 2017: Highlights of Advances in Viral Hepatitis and Liver Fibrosis.

Topics in antiviral medicine

Luetkemeyer AF, Wyles DL

Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients.

Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research

Nelson M, Rubio R, Lazzarin A, Romanova S, Luetkemeyer A, Conway B, Molina JM, Xu D, Srinivasan S, Portsmouth S

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.

Annals of internal medicine

Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL, C-EDGE CO-STAR Study Group

Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells.

PloS one

Saharia KK, Petrovas C, Ferrando-Martinez S, Leal M, Luque R, Ive P, Luetkemeyer A, Havlir D, Koup RA

A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries.

BMC infectious diseases

Godfrey C, Tauscher G, Hunsberger S, Austin M, Scott L, Schouten JT, Luetkemeyer AF, Benson C, Coombs R, Swindells S, HIV Network Coordinating (HANC) TB Diagnostic Laboratory Working Division of AIDS, National Institut

CROI 2016: Viral Hepatitis and Liver Fibrosis.

Topics in antiviral medicine

Luetkemeyer AF, Wyles DL

Tuberculosis Infection in Early Childhood and the Association with HIV-exposure in HIV-uninfected Children in Rural Uganda.

The Pediatric infectious disease journal

Marquez C, Chamie G, Achan J, Luetkemeyer AF, Kyohere M, Okiring J, Dorsey G, Kamya MR, Charlebois ED, Havlir DV

12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Luetkemeyer AF, McDonald C, Ramgopal M, Noviello S, Bhore R, Ackerman P

Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Luetkemeyer AF, Firnhaber C, Kendall MA, Wu X, Mazurek GH, Benator DA, Arduino R, Fernandez M, Guy E, Johnson P, Metchock B, Sattler F, Telzak E, Wang YF, Weiner M, Swindells S, Sanne IM, Havlir DV, Grinsztejn B, Alland D, AIDS Clinical Trials Group A5295 and Tuberculosis Trials Consortium Study 34 Teams

The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection.

Journal of acquired immune deficiency syndromes (1999)

Jacobson JM, Zheng L, Wilson CC, Tebas P, Matining RM, Egan MA, Eldridge J, Landay AL, Clifford DB, Luetkemeyer AF, Tiu J, Martinez AL, Janik J, Spitz TA, Hural J, McElrath J, Frahm N, ACTG A5281 Protocol Team

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

The New England journal of medicine

Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fishbein D, Gathe JC, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin PD, Noviello S, Ackerman P, ALLY-2 Investigators

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

The New England journal of medicine

Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M, ION-4 Investigators

Bartonella quintana Aortitis in a Man with AIDS, Diagnosed by Needle Biopsy and 16S rRNA Gene Amplification.

Journal of clinical microbiology

Lee SA, Plett SK, Luetkemeyer AF, Borgo GM, Ohliger MA, Conrad MB, Cookson BT, Sengupta DJ, Koehler JE

CROI 2015: Highlights of Viral Hepatitis Therapy.

Topics in antiviral medicine

Luetkemeyer AF, Wyles DL

Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Luetkemeyer AF, Rosenkranz SL, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, Sanne I, McIlleron H, Havlir DV, Haas DW, Adult AIDS Clinical Trials Group A5221 and A5243 Study Teams

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

JAMA

Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Rodriguez-Torres M, Dieterich D, PHOTON-1 Investigators

Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.

Antimicrobial agents and chemotherapy

Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW

CROI 2014: Viral hepatitis and complications of HIV disease and antiretroviral therapy.

Topics in antiviral medicine

Luetkemeyer AF, Havlir DV, Currier JS

HIV-associated central nervous system tuberculosis.

Seminars in neurology

Chamie G, Marquez C, Luetkemeyer A

Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs.

Journal of acquired immune deficiency syndromes (1999)

Luetkemeyer AF, Kendall MA, Nyirenda M, Wu X, Ive P, Benson CA, Andersen JW, Swindells S, Sanne IM, Havlir DV, Kumwenda J, Adult AIDS Clinical Trials Group A5221 Study Team

Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.

Journal of acquired immune deficiency syndromes (1999)

Marks KM, Kitch D, Chung RT, Hadigan C, Andersen J, Tien P, Luetkemeyer A, Alston-Smith B, Glesby MJ, A5239 Team

Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB.

Journal of clinical microbiology

Luetkemeyer AF, Kendall MA, Wu X, Lourenço MC, Jentsch U, Swindells S, Qasba SS, Sanchez J, Havlir DV, Grinsztejn B, Sanne IM, Firnhaber C, Adult AIDS Clinical Trials Group A5255 Study Team

Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial.

HIV clinical trials

Amorosa VK, Luetkemeyer A, Kang M, Johnson VA, Umbleja T, Haas DW, Yesmin S, Bardin MC, Chung RT, Alston-Smith B, Tebas P, Peters MG

Household ventilation and tuberculosis transmission in Kampala, Uganda.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Chamie G, Wandera B, Luetkemeyer A, Bogere J, Mugerwa RD, Havlir DV, Charlebois ED

Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F, Adult AIDS Clinical Trials Group A5221 Study Team

CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy.

Topics in antiviral medicine

Luetkemeyer AF, Havlir DV, Currier JS

Complications of HIV disease and antiretroviral therapy.

Topics in antiviral medicine

Luetkemeyer AF, Havlir DV, Currier JS

Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia.

Journal of acquired immune deficiency syndromes (1999)

Luetkemeyer AF, Charlebois ED, Hare CB, Black D, Smith A, Havlir DV, Peters MG

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.

The New England journal of medicine

Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I, AIDS Clinical Trials Group Study A5221

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

American journal of respiratory and critical care medicine

Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, Villarino ME, Weiner M, Benson C, Burman W, National Institutes of Health, Centers for Disease Control and Prevention

Tuberculosis drug development: ensuring people living with HIV are not left behind.

American journal of respiratory and critical care medicine

Luetkemeyer AF, Getahun H, Chamie G, Lienhardt C, Havlir DV

Complications of HIV disease and antiretroviral therapy.

Topics in antiviral medicine

Luetkemeyer AF, Havlir DV, Currier JS

Current issues in the diagnosis and management of tuberculosis and HIV coinfection in the United States.

Topics in HIV medicine : a publication of the International AIDS Society, USA

Luetkemeyer AF

Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Chamie G, Luetkemeyer A, Walusimbi-Nanteza M, Okwera A, Whalen CC, Mugerwa RD, Havlir DV, Charlebois ED

Tuberculosis as part of the natural history of HIV infection in developing countries.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Chamie G, Luetkemeyer A, Charlebois E, Havlir DV

Complications of HIV disease and antiretroviral treatment.

Topics in HIV medicine : a publication of the International AIDS Society, USA

Luetkemeyer AF, Havlir DV, Currier JS

Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals.

American journal of respiratory and critical care medicine

Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, Havlir DV

Antiretroviral therapy and TB.

Tropical doctor

Swaminathan S, Luetkemeyer A, Srikantiah P, Lin R, Charlebois E, Havlir DV

Clinical presentation and course of acute hepatitis C infection in HIV-infected patients.

Journal of acquired immune deficiency syndromes (1999)

Luetkemeyer A, Hare CB, Stansell J, Tien PC, Charlesbois E, Lum P, Havlir D, Peters M

Willing and able? Provision of medication for abortion by future internists.

Women's health issues : official publication of the Jacobs Institute of Women's Health

Schwarz EB, Luetkemeyer A, Foster DG, Weitz TA, Lindes D, Stewart FH

Custom People Group: